Navigation Links
Hepatitis C virus faces new weapon from Florida State scientists
Date:9/29/2010

In recent human trials for a promising new class of drug designed to target the hepatitis C virus (HCV) without shutting down the immune system, some of the HCV strains being treated exhibited signs of drug resistance.

In response, an interdisciplinary team of Florida State University biologists, chemists and biomedical researchers devised a novel genetic screening method that can identify the drug-resistant HCV strains and the molecular-level mechanisms that make them that way helping drug developers to tailor specific therapies to circumvent them.

The potentially life-saving technology also works when screening other viruses with drug-resistance issues, notably human immunodeficiency virus (HIV) and influenza.

More than 170 million people worldwide are infected with HCV, which leads to both acute and chronic liver diseases.

"In collaboration with pharmaceutical firm Gilead Sciences and researchers from the University of Heidelberg (Germany), what our research team discovered was how the latest drug for HCV works and what changes in the virus that makes it resistant to this unique therapy," said Hengli Tang, a Florida State University molecular biologist.

"This is knowledge that is essential to drug developers focused on HCV," said Tang, "but equally important is that our method, which we call 'CoFIM' (Cofactor-independent mutant) screening, can also be applied to other drug targets and other viruses.

"And, since we now understand how this latest class of drug works and what causes resistance to it, we can better select other classes of drugs with distinct mechanisms in other words, those that target other parts of the virus in order to craft a combination therapy, which is the future of HCV therapy and the key to overcoming drug resistance."

The groundbreaking research is described in a paper published online in the September 2010 issue of the journal PLoS Pathogens.

Florida State biology doctoral student Feng Yang led the research team. The award-winning scholar earned her Ph.D. in August 2010 and is now a postdoctoral associate at Yale University. Yang designed the CoFIM screening methodology with fellow FSU graduate students, postdoctoral associates and distinguished faculty colleagues including Associate Professor Tang; chemistry/biochemistry Professor Timothy M. Logan, director of FSU's Institute of Molecular Biophysics; and Research Assistant Professor Ewa A. Bienkiewicz, of the FSU College of Medicine, where she directs the Biomedical Proteomics Laboratory.

Driving the team's development of CoFIM screening was the need to identify key "cellular cofactors" and their mechanisms of action a fundamental aspect of virus-host interaction research.

"'Cellular cofactors' are proteins that normally exist in host cells that have been hijacked by viruses to facilitate viral replication." Tang said. "They became accomplices to the invading viruses.

"Our research team was the first to show that 'cyclophilin A' (CyPA) is an essential cellular cofactor for hepatitis C virus infection and the direct target of a new class of clinical anti-HCV compounds, which include cyclosporine A (CsA)-based drugs that are devoid of immunosuppressive function," Tang said.

"In addition, we went a step further than other research teams by employing our newly developed CoFIM screening method, which we used to demonstrate not only HCV's dependence on cellular cofactor cyclophilin A and susceptibility to cyclosporine A drugs but also to uncover the molecular-level regulators that determine those two traits in the virus."

Those molecular-level regulators are known as "small interfering RNA libraries" collections of molecules so named for their size and ability to suppress gene expression. They act to individually suppress every gene in the cell, resulting in different consequences depending upon which gene is suppressed by a given member in the library.

The CoFIM screening method involves inducing or "coaxing" the HCV virus to mutate by itself, in vitro, absent the replication assistance it normally receives from a particular cellular cofactor. Then, CoFIM tracks the changes in the virus's response both to CsA-based drugs and any other drug designed to inhibit the cofactor.


'/>"/>

Contact: Hengli Tang
tang@bio.fsu.edu
850-645-2402
Florida State University
Source:Eurekalert  

Related biology news :

1. Discovery of a hepatitis C-related virus in bats may reduce outbreaks in humans
2. Small genetic variant can predict response to hepatitis C treatment
3. New insights into treatment options for patients suffering from severe alcoholic hepatitis
4. Enzyme deficiency protects hepatitis C patients from treatment-related anemia
5. Natural compound blocks hepatitis C infection
6. Toward explaining why hepatitis B hits men harder than women
7. Largest-ever database for liver proteins may lead to treatments for hepatitis
8. The hepatitis healing power of blueberry leaves
9. First human gets new antibody aimed at hepatitis C virus
10. Novel antibody prevents infection by hepatitis C virus
11. Biolex presents Locteron US Phase 2a hepatitis C data at EASL
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Hepatitis C virus faces new weapon from Florida State scientists
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology: